Twist Bioscience Corporation $TWST Shares Bought by Baillie Gifford & Co.

Baillie Gifford & Co. raised its position in Twist Bioscience Corporation (NASDAQ:TWST) by 1.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,276,195 shares of the company’s stock after acquiring an additional 13,456 shares during the period. Baillie Gifford & Co. owned approximately 2.08% of Twist Bioscience worth $40,481,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quarry LP purchased a new stake in shares of Twist Bioscience during the third quarter valued at $28,000. Smartleaf Asset Management LLC grew its holdings in shares of Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares during the last quarter. National Bank of Canada FI purchased a new stake in shares of Twist Bioscience during the third quarter valued at $46,000. Geneos Wealth Management Inc. purchased a new stake in shares of Twist Bioscience during the second quarter valued at $97,000. Finally, CWM LLC grew its holdings in shares of Twist Bioscience by 61.4% during the third quarter. CWM LLC now owns 4,331 shares of the company’s stock valued at $122,000 after buying an additional 1,648 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TWST shares. Guggenheim boosted their price objective on shares of Twist Bioscience from $50.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 30th. Evercore boosted their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Finally, Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $46.50.

Insider Activity at Twist Bioscience

In related news, insider Dennis Cho sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $49.93, for a total transaction of $249,650.00. Following the completion of the transaction, the insider directly owned 138,581 shares in the company, valued at $6,919,349.33. The trade was a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 5,001 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $46.58, for a total transaction of $232,946.58. Following the transaction, the chief executive officer owned 869,312 shares of the company’s stock, valued at $40,492,552.96. This represents a 0.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 46,049 shares of company stock valued at $2,198,717 over the last ninety days. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Trading Up 5.2%

NASDAQ TWST opened at $50.38 on Tuesday. The company has a market capitalization of $3.09 billion, a PE ratio of -39.36 and a beta of 2.20. The company has a fifty day moving average of $47.85 and a 200 day moving average of $38.38. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The business’s revenue was up 16.9% compared to the same quarter last year. Research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.